Thursday, 29 July 2010
Commenting on the results, David Brennan, Chief Executive Officer, said:
"Our second quarter performance reflects continued strong growth in our Emerging Markets and good performance for key brands Crestor, Seroquel and Symbicort. While revenue and Core EPS comparisons become more challenging in the second half of the year, we have increased our full year financial targets."
Second quarter and half year results 2010
Announced on Thursday 29 July 2010